EWA
VTGN icon

EverSource Wealth Advisors’s VistaGen Therapeutics VTGN Stock Holding History

EverSource Wealth Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-88
Closed -$452 – 3000
2023
Q4 		$452 Hold
88
– – ﹤0.01% 2541
2023
Q3 		$461 Buy
+88
New +$391 ﹤0.01% 2392

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EverSource Wealth Advisors's VTGN Position: Q1 2024 in Review

EverSource Wealth Advisors sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 88 shares — an estimated $452 sold.

EverSource Wealth Advisors first reported a position in VTGN in Q3 2023 and held it in 2 quarters. The position peaked at $461 in Q3 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

  • EverSource Wealth Advisors reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EverSource Wealth Advisors sold 88 VistaGen Therapeutics shares in Q1 2024, an estimated $452.
  • EverSource Wealth Advisors first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 2 quarters.
  • EverSource Wealth Advisors's VistaGen Therapeutics position peaked at $461 in Q3 2023.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on EverSource Wealth Advisors's 13F filing for Q1 2024, filed 13 May 2024.